Article

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer Treatment

2025-07-04

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Tumor-infiltrating lymphocytes (TILs) have shown promise in cancer immunotherapy, but their clinical application and developmental trajectory remain insufficiently characterized. This study aimed to systematically analyze the features and trends of TIL-related clinical trials to inform future trial designs and translational research. <bold>Methods:</bold> W...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3ba15419-711e-5c16-bb6a-41e8acf763e2
DOI: 10.21203/rs.3.rs-6990012/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentDOI 10.21203/rs.3.rs-6990012/v1Read

Evolving or Immutable - Phase I Solid Tumor Trials in the Era of Precision OncologySemantic proximity Read

Holistic Understanding of the Current Landscape, Challenges, and Potential Advancements in the Integration of Immunotherapy with Traditional Cancer Treatments: A Narrative ReviewSemantic proximity Read

The Current Landscape of Clinical TrialsSemantic proximity Read

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysisSemantic proximity Read

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsSemantic proximity Read

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read

Current trends in cancer immunotherapy: a literature-mining analysis.Semantic proximity Read

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsSemantic proximity Read

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read

Maximizing the Anti-tumor Potential of Immune Checkpoint Blockade through Modulation of Myeloid-specific CXCL16 and STAT1 SignalingSemantic proximity Read

Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in MelanomaSemantic proximity Read

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapySemantic proximity Read